Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Genetic defect identified by AmBreed’s Technology

Press Release: Ambreed New Zealand.

Genetic defect identified by AmBreed’s Genomic Selection Technology

AmBreed New Zealand is urging other genetic companies to follow its lead to identify and remove animals carrying a damaging genetic defect.

Brachyspina (BY), causes a minority of cows to produce still born calves with deformed organs and elongated limbs.

A genetic marker test for the rare genetic defect has been developed by Ambreed New Zealand’s Dutch parent company CRV following the release of its world-leading inSire Genomic Selection technology. Here in New Zealand, Ambreed is taking the lead and using the new test to prevent new carrier animals from entering the market.

The marker test was developed by CRV in co-operation with Animal Health Services in Netherlands, Denmark’s University of Copenhagen and the University of Luik, in Belgium. It will be used by the company when DNA testing potential sires through its inSire Breeding Programs. Other genetics companies around the world can screen their animals through CRV in Holland.

CRV’s research traces the origin of the defect to a single bull, Sweet Haven Tradition. This bloodline will have had some impact on the New Zealand population through his son Bis-May Tradition Cleitus.

AmBreed New Zealand managing director Jos Koopman said while the number of carriers was expected to be very low in New Zealand, they could be identified quickly if the marker test was applied.

AmBreed New Zealand had also successfully identified the condition CVM in New Zealand, ensuring no new carriers were released by AmBreed onto the New Zealand market.

“We will follow the same process with BY as we did with CVM, and will not be selecting BY positive bulls in our breeding program,” said Jos Koopman.

He said identifying the BY defect would give New Zealand farmers confidence in using AmBreed sires with the assurance AmBreed’s global research reduced genetic risk while boosting genetic gain.


ENDS

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.